Roussel Uclaf

About: Roussel Uclaf is a based out in . It is known for research contribution in the topics: Alkyl & Alkoxy group. The organization has 1888 authors who have published 2338 publications receiving 36508 citations.

Indole derivatives, their preparation, their use as medicines and compositions containing them

Abstract: La presente invention concerne les composes (1), et leurs sels avec les acides: The present invention relates to compounds (1) and their salts with acids: ou R est hydrogene, alkyle (C 1-8 ), aralkyle (C 7-12 ), Z est hydrogene, alkyle (C 1-8 ), alkenyle (C 2-8 ), cyanoalkyle (C 3-8 ), hydroxyalkyle (C 2-8 ), -(CH 2 ) n -O-Ar, wherein R is hydrogen, alkyl (C 1-8), aralkyl (7-12 C), Z is hydrogen, alkyl (C 1-8), alkenyl (C 2-8) cyanoalkyl, (C 3-8) hydroxyalkyl (C 2-8), - (CH 2) n -O-Ar, n varie de 2 a 8 et Ar est aryle ou heteroaryle (eventuellement substitue par alkyle (C 1-5 ), alkoxy (C 1-5 ), halogene, OH, hydroxyalkyle (C 1-5 ), alkenyle, alkenyloxy, alkynyle, alkynyloxy, nitro, amino, CF 3 ) ou Z est un aralkyle (C 7-12 ) (eventuellement substitue par alkyle (C 1-5 ), alkoxy (C 1-5 ), halogene, OH, CF 3 OCF 3 N0 2 , NH 2 ) ou Z est un cycloalkylalkyle (C 4-12 ) et a et b representent chacun un hydrogene, ou a est hydrogene et b est OH ou alkoxy, ou a et b forment une liaison carbone-carbone et le groupement 2-oxo en pointilles signifie la presence eventuelle de ce groupement. n ranges from 2 to 8 and Ar is aryl or heteroaryl (optionally substituted by alkyl (1-5 C), alkoxy (1-5 C), halogen, OH, hydroxy (C 1-5), alkenyl, alkenyloxy, alkynyl, alkynyloxy, nitro, amino, CF 3), or Z is aralkyl (C 7-12) (optionally substituted by alkyl (1-5 C), alkoxy (1-5 C), halogen, OH, CF 3 OCF 3 N0 2 , NH 2) or Z is a cycloalkyl (C 4-12) and a and b each represent hydrogen, or a is hydrogen and b is OH or alkoxy, or a and b form a carbon-carbon bond and the group 2- oxo dashed means the presence of this group. L'invention concerne aussi un procede de preparation des composes de formule (1), leur application comme medicament et les compositions les renfermant. The invention also relates to a process for preparing the compounds of formula (1), their application as medicaments and compositions containing them.

Use of milk proteins in making antiviral drugs

Abstract: Use of milk proteins, in particular those capable of binding iron, in making an antiviral drug which is useful in the treatment of conditions caused by enveloped viruses, as well as conditions caused by naked viruses.

Peptide having antihypertensive activity free of vascoconstrictor activity

Abstract: A peptide derivative having the formula: ##STR1## wherein X1 is hydrogen or cysteine residue, X3 is a cysteine or alanine residue, X4 is a residue of asparagine, phenylalanine, leucine, isoleucine, alanine, valine, glycine and their homologues in the D series, X6 is a residue of tryptophan, phenylalanine, leucine, isoleucine, alanine, valine, glycine, serine, lysine, aspartic acid, tyrosine, threonine and their homologues in the D series, X9 and X17 are a residue of glutamic acid, aspartic acid, lysine, arginine, tyrosine, leucine and their homologues in the D series, X11 is a cysteine or alanine residue, X14 is a residue of tyrosine, phenylalanine, leucine, isoleucine, alanine, valine, glycine, serine, lysine, aspartic acid, threonine and their homologues in the D series, X21 is hydrogen or a tryptophan or D-tryptophan residue, and the derivatives possessing, where appropriate, one or two disulfide bridges, with the proviso that X21 cannot be a tryptophan residue when X1, X3 and X11 are a cysteine residue, X4 is an asparagine residue, X6 is a tryptophan residue, X9 is a lysine residue, X14 is a phenylalanine residue and X17 is a leucine residue having antihypertensive activity free of vasoconstrictor activity.